Emerging Topic Conference 2025: MASLD, MetALD and ALD: Challenges and Opportunities - (On-Demand)
Image For Activity Cover
Availability
On-Demand
10 Courses
Cost
Member: $200.00
Non-Member: $400.00
Patient: $0.00
Associate: $125.00
Student: $0.00
Early Career: $125.00
Industry Rep: $400.00
Credit Offered
32 AMA PRA Category 1 Credits
32 Participation Credits
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Recommended
Experience the “MASLD, MetALD, and ALD: Challenges and Opportunities” Emerging Topic Conference (ETC) at your convenience with our on-demand offering. This comprehensive program delves into the latest advancements in the management of Steatotic Liver Diseases (SLD), with a special focus on the evolving landscape of Metabolic and Alcohol-associated Liver Disease (MetALD). These sections will present topics on pre-clinical and translational data on MetALD, epidemiology and population health, MetALD Challenges and Opportunities, MASH targeted therapies including obesity medicine and the evolving clinical practice and trials.

Led by renowned experts, this dynamic three-day event covered critical topics, including clinical practice updates, innovative treatment strategies, and groundbreaking research shaping the future of liver disease management. Gain insights from leading professionals, explore cutting-edge developments, and stay ahead in the field—all on your schedule.

This ondemand course is based on the recent live activity, Emerging Topic Conference 2025. While this ondemand course offers continuing education credits, the learner should only accept credit for the sessions that are participated in for the ondemand activity.


This activity is sponsored by an unrestricted educational grant by Madrigal Pharmaceuticals.
Upon completion of this activity, participants should be able to:

• Describe the details of the pathophysiology, disease burden, and diagnosis for MASLD, MetALD, and ALD
• Identify the emerging trends and research needs in MetALD.
• Explore the challenges and opportunities in integrating MASLD and ALD management.
• Discuss the future directions and innovations in the field of SLD.
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material for a maximum of 16.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD CME Committee, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education. The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes.

All relevant conflicts pertaining to this activity have been mitigated. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

FACULTY:

Alina Allen, MD

Scientific Consultant/Advisor: Ionis Pharmaceuticals, Inc.

Ali Aminian, MD
Scientific Consultant/Advisor: Eli Lilly, Ethicon, Medtronic
Research Grants: Ethicon, Medtronic

Naim Alkhouri, MD, FAASLD:
Scientific Consultant/Advisor: Intercept, Pfizer, Gilead, Echosens, Fibronostics, LG Chem, Novo Nordisk, 89Bio, Akero, Perspectum, Galecto, NorthSea, Merck, Altimmune
Research Grants: 89Bio, Akero, AbbVie/Allergan, Altimmune, Better Therapeutics, Boehringer Ingelheim, Bristol MyersSquibb, Corcept, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus
Speakers Bureau: Intercept, Gilead, AbbVie, Alexion, Echosens, Perspectum, Exelixis

Meena Bansal, MD, FAASLD:
Scientific Consultant/Advisor: Kinetix Group; Boehringer-Ingelheim

Fernando Bril, MD:
Scientific Consultant/Advisor: NovoNordisk, Boehringer Ingelheim

Kenneth Cusi, MD, FACP, FACE
Scientific Consultant/Advisor: Aligos Therapeutics, Arrowhead, AstraZeneca, 89Bio, BMS, Boehringer Ingelheim, GSK, Eli Lilly & Co, Novo Nordisk, Prosciento, Sagimet Biosciences, Siemens USA and Terns Pharma Research Grants: Inventiva, Echosens, Boehringer Ingelheim, Perspectum, LabCorp

Luis Antonio Diaz:
Nothing to Disclose

Anna Mae Diehl, MD, FAASLD:
Nothing to Disclose

Pichamol Jirapinyo, MD:
Scientific Consultant/Advisor: Boston Scientific, Cook Medical, ERBE, Fractyl, Spatz Medical
Research Grants: Boston Scientific, GI Dynamics, Fractyl, USGI Medical
Stock Options- Privately Held: Bariando

Jenn Jones, BA
Contractor: Boehringer Ingelheim

Kathy Jung, PhD
Nothing to Disclose

W. Ray Kim, MD, FAASLD
Scientific Consultant/Advisor: Grifols, Gilead Sciences

Aleksander Krag, MD, PhD
Nothing to Disclose

Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD
Scientific Consultant/Advisor: TwoXar, Surrozen, Durect, Korro Bio

Rohit Loomba, MD, MHSc, FAASLD
Employee: LipoNexus
Scientific Consultant/Advisor: Aardvark, Altimmune, Arrowhead, AstraZeneca, Cascade, Eli Lilly, Gilead, Glympse Bio, Inipharma, Intercept, Inventiva, Ionis, Janssen, Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet Biosciences, Takeda, 89bio, Terns, Viking
Research Grants: Arrowhead, AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hammi, Inventiva, Ionis, Janssen, Madrigal, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns

Michael Lucey, MD, FAASLD
Scientific Consultant/Advisor: Novartis
Research Grants: PharmaSolutions; Intercept Pharma; Exact Sciences

Pranoti Mandrekar, PhD, FAASLD
Nothing to Disclose

Philippe Mathurin, MD, PhD
Board Membership: Bristol Myers-Squibb, Gilead, AbbVie, Eisai, Intercept, Ipsen, Bayer, Novo Nordisk, Pfizer
Scientific Consultant/Advisor: Bristol Myers-Squibb, Gilead, AbbVie, Eisai, Intercept, Ipsen, Bayer, Novo Nordisk, Pfizer

Craig McClain, MD, FAASLD
Scientific Consultant/Advisor: US Federal Trade Commission
Research Grants: NIH, VA, Intercept, Target Pharma Solutions, Altimmune

Jessica Mellinger, MD
Scientific Consultant/Advisor: GlaxoSmithKline

Mary Rinella, MD, FAASLD
Scientific Consultant/Advisor: Boehringer Ingelheim, Intercept, GlaxoSmithKline, Eli Lilly, Madrigal, NovoNordisk, Cytodyn, HistoIndex, Sonic Incytes, 89Bio, Akero, NGM Biopharmaceuticals, Sagimet

Juan Pablo Arab, MD, FRCPC
Nothing to Disclose

Jurgen Rehm, MD, FRCPC
Nothing to Disclose

Arun Sanyal, MD, FAASLD
Scientific Consultant/Advisor: Target Pharmasolutions
Research Grants: Astra Zeneca, Intercept, Pfizer, Merck, Bristol Myers Squibb, Eli Lilly, Echosens, Novo Nordisk, Boehringer Ingelheim, Novartis, Madrigal
Intellectual Property Rights: UpToDate, Elsevier

Ashwani Singal, MD, MS, FACS, FAASLD
Scientific Consultant/Advisor: Pleiogenix, GSK, Madrigal, CLD Foundation, Medscape Gastroenterology, Medical Speaker's Network, Up-To-Date Research Grants: American College of Gastroenterology, National Institute of Alcohol Abuse and Alcoholism, Pleiogenix SBIR

Douglas Simonetto, MD
Scientific Consultant/Advisor: Mallinckrodt; BioVie

Tram Tran
Scientific Consultant/Advisor: Gilead, Bristol Myers-Squibb, AbbVie, Merck
Research Grants: Gilead, AbbVie, Bristol Myers-Squibb

Gyongyi Szabo, MD, PhD, FAASLD
Scientific Consultant/Advisor: Analym Pharma, Intercept, Novartis, Generon, Allergan, Glympse Bio
Research Grants: Gilead

Norah Terrault, MD, MPH, FAASLD
Nothing to Disclose

Miriam Vos, MD, MSPH, FAASLD
Scientific Consultant/Advisor: Eli Lilly, Bristol Myers-Squibb, Boehringer Ingelheim, Intercept, Prosciento, Theogenisis
Research Grants: AMRA, Quest, Gemfire, Sonic Incytes

Tiffany Wu, MD, MS
Nothing to Disclose

Zobair Younossi, MD, MPH, FAASLD
Scientific Consultant/Advisor: Gilead, Intercept, Merck, Bristol Meyer, Siemens, Novo Nordisk, Madrigal, Abbott, Cymabay, GlaxoSmithKline

PLANNING COMMITTEE:

Juan Pablo Arab, MD, FRCPC
Nothing to Disclose

Sumeet Asrani, MD, MSc
Nothing to Disclose

Bilal Hameed, MD, FAASLD
Scientific Consultant/Advisor: Mallinckrodt, Pliant Therapeutics
Research Grants: Novo Nordisk, Gilead, Genfit, Pleiogenix, Intercept

Mazen Nourredin, MD, MHSc
Scientific Consultant/Advisor: Altimmune, BI, Cytodyn, Corcept, 89BIO, GSK, Madrigal, Merck, Novo Nordisk, Northsea Therapeutics, Perspectum, Siemens,Terns and Takeda
Research Grants: Allergan, Akero, BMS, BI, Gilead, Galectin, Genfit, GSK, Conatus, Corcept, Enanta, Madrigal, Novartis, Novo Nordisk, Shire, Takeda, Terns, Viking and Zydus

Mary Rinella, MD, FAASLD
Scientific Consultant: Boehringer Ingelheim, Intercept, GlaxoSmithKline, Eli Lilly, Madrigal, NovoNordisk, Cytodyn, HistoIndex, Sonic Incytes, 89Bio, Akero, NGM Biopharmaceuticals, Sagimet

Vijay Shah, MD, FAASLD
Scientific Consultant/Advisor: Novartis Pharma, Generon Shanghai, HepaRegniX, Mallinckrodt, Korro Bio, Seal Rock Therapeutics, Akaza Bioscience, AgomAb Therapeutics, Resolution Therapeutics, Intercept

REVIEWERS AND STAFF:

Steven Folstein, MFA, M.Ed.
Nothing to Disclose

Sally Cook, CMP, CHCP
Nothing to Disclose
Powered By